India's Biocon on Generic GLP-1 Push

🇮🇳 Bloomberg (IN) —

AI Summary

Biocon is focusing on expanding its footprint in the generic GLP-1 market, responding to competitor Novo Nordisk's price cuts on popular diabetes and weight-loss medications. This strategic shift is part of Biocon's broader growth strategy as it seeks to enhance its product offerings in India.

Biocon CEO, Shreehas Tambe, discusses their push into the generic GLP-1 market, after Novo Nordisk cut prices of its blockbuster weight-loss and diabetes medications in India. He also spoke about the company's latest set of earnings on Insight with Haslinda Amin. (Source: Bloomberg)

Markets Health Biocon GLP-1 Novo Nordisk generic medications India

Read original source →